BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation.

Clario, a technology company that delivers the leading endpoint solutions for decentralized, hybrid and site-based clinical trials, announced that Otis Johnson, Ph.D., Chief Diversity, Inclusion and Sustainability Officer, has been named one of PharmaVoice’s 100 most inspiring individuals in the life-sciences industry.

Spine BioPharma, Inc., a company committed to developing non-opiate, non-surgical therapies for the treatment of Chronic Low Back Pain (CLBP) and related disability caused by Degenerative Disc Disease (DDD), today announced the first patient treated in a Phase 3 clinical study of SB-01 For Injection (SB-01).

Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion technology, announced the appointment of James Reinstein as President and Chief Executive Officer.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

RenovoRx, Inc. announced management’s participation in the upcoming H.C. Wainwright 24th Annual Global Investment Conference.

Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences in September:.

Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the European Medicines Agency (EMA) has classified the Company’s lead gene therapy product candidate, rAAV-Olig001-ASPA for the treatment of Canavan disease, as an Advanced Therapy Medicinal Product (ATMP), specifically a Gene Therapy Medicinal Product (GTMP).

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference taking place September 12-14, 2022 in New York City.

Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio.